Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics, Inc. (TNYA)
:TNYA
Total Valuation
Tenaya Therapeutics has a market cap or net worth of $74.52M. The enterprise value is $75.72M.
Market Cap$74.52M
Enterprise Value$75.72M
Share Statistics
Tenaya Therapeutics has 162,634,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding162,634,580
Owned by Insiders72.98%
Owned by Institutions0.03%
Financial Efficiency
Tenaya Therapeutics’s return on equity (ROE) is -1.20 and return on invested capital (ROIC) is -108.62%.
Return on Equity (ROE)-1.20
Return on Assets (ROA)-0.93
Return on Invested Capital (ROIC)-108.62%
Return on Capital Employed (ROCE)-1.12
Revenue Per Employee0.00
Profits Per Employee-1.15M
Employee Count97
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tenaya Therapeutics is -1.09. Tenaya Therapeutics’s PEG ratio is 0.05.
PE Ratio-1.09
PS Ratio―
PB Ratio1.31
Price to Fair Value1.31
Price to FCF-1.33
Price to Operating Cash Flow-1.34
PEG Ratio0.05
Income Statement
In the last 12 months, Tenaya Therapeutics had revenue of 0.00 and earned -111.13M in profits. Earnings per share was -1.31.
Revenue0.00
Gross Profit0.00
Operating Income-115.95M
Pretax Income-111.13M
Net Income-111.13M
EBITDA-115.95M
Earnings Per Share (EPS)-1.31
Cash Flow
In the last 12 months, operating cash flow was -90.50M and capital expenditures -1.02M, giving a free cash flow of -91.53M billion.
Operating Cash Flow-90.50M
Free Cash Flow-91.53M
Free Cash Flow per Share-0.56
Dividends & Yields
Tenaya Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.96
52-Week Price Change-89.66%
50-Day Moving Average0.71
200-Day Moving Average1.92
Relative Strength Index (RSI)37.54
Average Volume (3m)3.91M
Important Dates
Tenaya Therapeutics upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateMar 10, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Tenaya Therapeutics as a current ratio of 4.22, with Debt / Equity ratio of 14.66%
Current Ratio4.22
Quick Ratio4.22
Debt to Market Cap0.11
Net Debt to EBITDA-0.08
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tenaya Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tenaya Therapeutics EV to EBITDA ratio is -1.13, with an EV/FCF ratio of -1.43.
EV to Sales0.00
EV to EBITDA-1.13
EV to Free Cash Flow-1.43
EV to Operating Cash Flow-1.44
Balance Sheet
Tenaya Therapeutics has $61.45M in cash and marketable securities with $13.61M in debt, giving a net cash position of -$47.84M billion.
Cash & Marketable Securities$61.45M
Total Debt$13.61M
Net Cash-$47.84M
Net Cash Per Share-$0.29
Tangible Book Value Per Share$1.09
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tenaya Therapeutics is $10.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.14
Price Target Upside2104.35% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast23.55%